OTCMKTS:ASPCF Acerus Pharmaceuticals (ASPCF) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free ASPCF Stock Alerts $0.22 0.00 (0.00%) (As of 07/21/2023) Add Compare Share Share Today's Range$0.22▼$0.2250-Day Range$0.22▼$0.2252-Week Range$0.22▼$8.16VolumeN/AAverage Volume1,500 shsMarket Capitalization$1.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Acerus Pharmaceuticals alerts: Email Address Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About Acerus Pharmaceuticals Stock (OTCMKTS:ASPCF)Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.Read More ASPCF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASPCF Stock News HeadlinesMarch 14, 2023 | finance.yahoo.comAcerus Announces Commencement of Court-Approved Sale and Investment Solicitation ProcessJanuary 16, 2023 | theglobeandmail.comAcerus Pharmaceuticals: Top 10 Undervalued Nano Cap Stocks on TSX (ASP)May 2, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.November 15, 2022 | finance.yahoo.comAcerus Reports Third Quarter 2022 Financial ResultsOctober 3, 2022 | finance.yahoo.comAcerus Announces Amendment to Promissory Note Due to Former Serenity ShareholdersSeptember 21, 2022 | marketwatch.comAcerus Pharmaceuticals to Initiate Strategic Review of OperationsSeptember 21, 2022 | finance.yahoo.comAcerus Announces Initiation of Strategic ReviewAugust 23, 2022 | seekingalpha.comAcerus Pharmaceuticals CFO resigns effective November 20, 2022May 2, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.August 14, 2022 | seekingalpha.comAcerus Pharmaceuticals Corporation (ASPCF) CEO Edward Gudaitis on Q2 2022 Results - Earnings Call TranscriptAugust 5, 2022 | finance.yahoo.comAcerus Announces Amendments to Loan Facility and Promissory Note Due to Former Serenity ShareholdersJune 27, 2022 | finance.yahoo.comAcerus Announces Voting Results for the 2022 Annual MeetingJune 24, 2022 | seekingalpha.comAcerus Pharmaceuticals increases loan facility to $37.94MMay 11, 2022 | seekingalpha.comAcerus Pharmaceuticals GAAP EPS of $0.00, revenue of $0.78MMay 5, 2022 | finance.yahoo.comAcerus To Report Q1-2022 Financial Results And Host Investor CallApril 26, 2022 | finance.yahoo.comAcerus Announces Completion of Share ConsolidationApril 19, 2022 | finance.yahoo.comAcerus Announces Share ConsolidationFebruary 28, 2022 | seekingalpha.comAcerus to acquire Florida-based Serenity in cash/stock dealFebruary 28, 2022 | stockhouse.comAcerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva(TM)February 28, 2022 | finance.yahoo.comAcerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva™See More Headlines Receive ASPCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ASPCF CUSIPN/A CIKN/A Webwww.aceruspharma.com Phone(416) 679-0771Fax905-569-1809Employees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,820,000.00 Net Margins-924.33% Pretax Margin-924.33% Return on EquityN/A Return on Assets-74.62% Debt Debt-to-Equity RatioN/A Current Ratio0.67 Quick Ratio0.34 Sales & Book Value Annual Sales$2.12 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value($3.38) per share Price / Book-0.07Miscellaneous Outstanding Shares7,708,000Free FloatN/AMarket Cap$1.70 million OptionableNot Optionable Beta0.69 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesEdward GudaitisPresident, CEO & Non-Independent DirectorNaveed ManzoorChief Financial OfficerChristopher SorliChief Medical OfficerPhilippe SavardSecretary, Senior Vice President & General CounselChris WittyInvestor Relations ContactKey CompetitorsMallinckrodtOTCMKTS:MNKKQBriaCell TherapeuticsOTCMKTS:BCTXFNeuBase TherapeuticsNASDAQ:NBSEPainReformNASDAQ:PRFXAoxing PharmaceuticalOTCMKTS:AOXGView All Competitors ASPCF Stock Analysis - Frequently Asked Questions How have ASPCF shares performed in 2024? Acerus Pharmaceuticals' stock was trading at $0.22 at the start of the year. Since then, ASPCF stock has increased by 0.0% and is now trading at $0.22. View the best growth stocks for 2024 here. When did Acerus Pharmaceuticals' stock split? Shares of Acerus Pharmaceuticals reverse split before market open on Friday, April 29th 2022. The 1-200 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Acerus Pharmaceuticals? Shares of ASPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ASPCF) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits4 Cryptos BETTER than BitcoinTrue Market InsidersThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
